220 related articles for article (PubMed ID: 19266094)
1. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.
Almendro V; Ametller E; García-Recio S; Collazo O; Casas I; Augé JM; Maurel J; Gascón P
PLoS One; 2009; 4(3):e4728. PubMed ID: 19266094
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.
Ametller E; García-Recio S; Pastor-Arroyo EM; Callejo G; Carbó N; Gascón P; Almendro V
Cancer Biol Ther; 2011 Jan; 11(1):4-13. PubMed ID: 20980803
[TBL] [Abstract][Full Text] [Related]
3. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
4. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.
Lei G; Liu S; Yang X; He C
Can J Gastroenterol Hepatol; 2021; 2021():8870907. PubMed ID: 33824865
[TBL] [Abstract][Full Text] [Related]
5. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
6. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
[TBL] [Abstract][Full Text] [Related]
7. Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis.
Griffiths GJ; Koh MY; Brunton VG; Cawthorne C; Reeves NA; Greaves M; Tilby MJ; Pearson DG; Ottley CJ; Workman P; Frame MC; Dive C
J Biol Chem; 2004 Oct; 279(44):46113-21. PubMed ID: 15326164
[TBL] [Abstract][Full Text] [Related]
8. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
McDermott U; Longley DB; Galligan L; Allen W; Wilson T; Johnston PG
Cancer Res; 2005 Oct; 65(19):8951-60. PubMed ID: 16204068
[TBL] [Abstract][Full Text] [Related]
9. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
[TBL] [Abstract][Full Text] [Related]
11. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity.
Micheau O; Solary E; Hammann A; Martin F; Dimanche-Boitrel MT
J Natl Cancer Inst; 1997 Jun; 89(11):783-9. PubMed ID: 9182976
[TBL] [Abstract][Full Text] [Related]
14. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
15. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.
Meng RD; Shelton CC; Li YM; Qin LX; Notterman D; Paty PB; Schwartz GK
Cancer Res; 2009 Jan; 69(2):573-82. PubMed ID: 19147571
[TBL] [Abstract][Full Text] [Related]
16. The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells.
Wang X; Li M; Wang J; Yeung CM; Zhang H; Kung HF; Jiang B; Lin MC
Biochem Pharmacol; 2006 May; 71(11):1540-50. PubMed ID: 16595125
[TBL] [Abstract][Full Text] [Related]
17. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.
Pirpour Tazehkand A; Akbarzadeh M; Velaie K; Sadeghi MR; Samadi N
Biomed Pharmacother; 2018 Jul; 103():755-766. PubMed ID: 29684854
[TBL] [Abstract][Full Text] [Related]
18. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
[TBL] [Abstract][Full Text] [Related]
19. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.
Arango D; Wilson AJ; Shi Q; Corner GA; Arañes MJ; Nicholas C; Lesser M; Mariadason JM; Augenlicht LH
Br J Cancer; 2004 Nov; 91(11):1931-46. PubMed ID: 15545975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
